MN-DTN
31.3.2020 15:02:06 CEST | Business Wire | Press release
Weather is always a factor when considering the safety of lives and structures, but with the overwhelming response to the COVID-19 crisis and the volatility of spring weather these risks are amplified. Triage tents and other temporary outdoor structures are extremely vulnerable to weather events, as are other lifesaving operations. Hospitals may not be able to relocate patients during hazardous weather and first response efforts may be challenging.
That is why DTN, an independent source of insights, analysis and decision-support solutions, announced today that it is supporting hospitals, medical institutions, public health agencies, and first responders worldwide by offering its premier weather app service WeatherSentry at no cost during the COVID-19 pandemic.
“At DTN we are committed to providing our insights to support those who feed, fuel and protect our world,” said Mike Eilts, DTN senior vice president-weather. “Our healthcare workers and organizations are on the frontlines of protecting citizens worldwide and, in some cases, working in less-than-ideal structures. It is important that they have access to the best weather information available at their fingertips should the need arise, so they can quickly react and ensure the safety of their patients and themselves in the event of severe weather.”
Healthcare workers, hospitals, public health agencies and first responders globally can register for two free months of WeatherSentry. The subscription includes web and mobile app access to professional-grade alerting for mobile positions and fixed locations; real-time lightning display and alerts; severe weather storm tracks via radar; hourly and 15-day forecasts; and access to DTN meteorologists 24 hours a day, seven days a week.
“DTN has long been there, supporting our customers globally with unmatched insights during difficult situations, such as extreme weather events and customers working outdoors,” said Eilts. “We are proud to be providing WeatherSentry to support our world’s healthcare organizations and first responders when they need the information the most.”
Forecast timing and accuracy, as well as real-time alerts are crucial to lessening the impact to lives during dangerous weather situations. WeatherSentry users get access to precise, accurate, and reliable weather information delivered in a single screen, and updated as conditions change.
WeatherSentry is available for Android phone and tablet users at the Google Play store and for iOS devices on the App store once the free subscription has been authorized. To learn more and to sign up for the complimentary service, visit the DTN WeatherSentry for COVID-19 responders page.
About DTN
DTN delivers accurate, objective, real-time, and actionable insights to increase customers’ confidence and support business decisions. In a data-rich world, these actionable insights in weather and financial analytics make sense of the information, drive change in processes and help businesses prosper. DTN empowers agriculture, energy and transportation customers – those who work endlessly to feed, fuel and protect our world. We believe that when our customers are supported with the most reliable and innovative information to the Nth Degree, they prosper and we all win. DTN’s highly accurate and reliable solutions are backed by more than 140 patents. The company publishes Progressive Farmer magazine, the premier publication in agriculture, and is headquartered in Minneapolis, Minnesota.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
